01 About

Founded in 2025, Elora Therapeutics is pioneering a systemically delivered enzyme therapeutic to break down microplastics inside the human body, an emerging driver of chronic inflammation, endocrine disruption, and disease with no FDA-approved treatment.

Our patent-pending formulation is engineered to degrade the four most common plastic polymers found in human tissues—Polyethylene Terephthalate (PET), Polyethylene (PE), Polypropylene (PP), and Polystyrene (PS)—breaking them down into safe, excretable byproducts. By uniting advanced enzyme design with translational science, Elora is charting a new course in molecular medicine.

We are advancing early validation efforts on the road to clinical development. Our team brings together scientists and entrepreneurs committed to addressing synthetic burden at its biological root.

02 Science

Our lead therapeutic is composed of four engineered enzyme variants optimized for broad-spectrum microplastic degradation within the human body.

Microplastics are increasingly recognized as bioactive pollutants, not inert bystanders. Once they enter the bloodstream and tissues, they interfere with cellular function, trigger oxidative stress, impair hormonal signaling, and contribute to chronic inflammation. Their presence has been linked to metabolic dysfunction, infertility, and disease pathways, to include cancer, yet no therapeutic options currently exist to address their accumulation in the human body.

At Elora, we’re developing a first-of-its-kind therapeutic: a systemically delivered enzyme composition designed to degrade microplastics in vivo. Unlike environmental enzymes, ours are optimized for human physiology, stable in serum, active at physiological pH, and capable of transforming synthetic polymers into small, excretable monomers.

Our current formulation targets four high-prevalence polymers in the human body: PET, PE, PP, and PS. In collaboration with leading academic partners, we are conducting early-stage validation studies to assess enzyme activity, stability, and biocompatibility in biologically relevant systems.

This is molecular intervention at the root cause—science built to address a modern, synthetic threat.

04 Contact

At Elora, we are committed to bringing novel therapies to patients. Reach out to learn more.

To request information, please use the form below.

Elora Therapeutics, Inc.

5900 Balcones Dr, Ste 9059

Austin, Texas 78731